These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17647245)

  • 1. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.
    Chia SK; Speers CH; D'yachkova Y; Kang A; Malfair-Taylor S; Barnett J; Coldman A; Gelmon KA; O'reilly SE; Olivotto IA
    Cancer; 2007 Sep; 110(5):973-9. PubMed ID: 17647245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
    Kono M; Fujii T; Lyons GR; Huo L; Bassett R; Gong Y; Karuturi MS; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2016 Nov; 160(1):101-109. PubMed ID: 27663436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
    Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
    Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
    Galy G; Labidi-Galy SI; Perol D; Bachelot T; Ray-Coquard I; Tredan O; Biron P; Latour JF; Blay JY; Guastalla JP; Favier B
    Breast Cancer Res Treat; 2011 Jul; 128(1):187-95. PubMed ID: 21184270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
    Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
    Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis.
    Lord SJ; Marinovich ML; Patterson JA; Wilcken N; Kiely BE; Gebski V; Crossing S; Roder DM; Gattellari M; Houssami N
    Med J Aust; 2012 Jun; 196(11):688-92. PubMed ID: 22708766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
    Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Kaufman B; Mackey JR; Clemens MR; Bapsy PP; Vaid A; Wardley A; Tjulandin S; Jahn M; Lehle M; Feyereislova A; Révil C; Jones A
    J Clin Oncol; 2009 Nov; 27(33):5529-37. PubMed ID: 19786670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Survival and Cure in Distant Metastatic Breast Cancer.
    Güth U; Elfgen C; Montagna G; Schmid SM
    Oncology; 2019; 97(2):82-93. PubMed ID: 31055570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
    PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.
    Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
    Breast Cancer Res Treat; 2011 Nov; 130(2):553-60. PubMed ID: 21617918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
    Cabuk D; Basaran G; Teomete M; Dane F; Korkmaz T; Seber S; Telli F; Yumuk PF; Turhal S
    Asian Pac J Cancer Prev; 2014; 15(1):117-22. PubMed ID: 24528011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
    Gennari A; Conte P; Rosso R; Orlandini C; Bruzzi P
    Cancer; 2005 Oct; 104(8):1742-50. PubMed ID: 16149088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
    He M; Li JJ; Zuo WJ; Ji L; Jiang YZ; Hu XC; Wang ZH; Shao ZM
    Cancer Med; 2019 Oct; 8(14):6212-6220. PubMed ID: 31373147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.